Ex-Cel­gene ex­ec steers his biotech start­up to Hong Kong IPO as po­ten­tial can­cer drug launch looms

Jay Mei re­mem­bers the ex­act date he first met BeiGene CEO John Oyler.

It was May 14, 2016, and Mei — then an ex­ec­u­tive di­rec­tor of clin­i­cal de­vel­op­ment at Cel­gene — ac­com­pa­nied CEO Mark Alles on a trip from New Jer­sey to Bei­jing. The meet­ing ce­ment­ed more than just Cel­gene’s ground­break­ing part­ner­ship with BeiGene, in which the Chi­na-based biotech of­fered its PD-1 in­hibitor in ex­change for Cel­gene’s com­mer­cial op­er­a­tion in the coun­try.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER